Tajak Richard J. 4
4 · APP Pharmaceuticals, Inc. · Filed Sep 15, 2008
Insider Transaction Report
Form 4
Tajak Richard J.
Exec. VP & CFO
Transactions
- Disposition to Issuer
Incentive Stock Option
2008-09-10$12.80/sh−35,000$448,000→ 0 totalExercise: $10.20Exp: 2018-04-09→ Common Stock (35,000 underlying)
Footnotes (1)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2008, among Fresenius SE, Fresenenius Kabi Pharmaceuticals Holding, Inc. (formerly Frensenius Kabi Pharmaceuticals Holding LLC), Fresenius Kabi Pharmaceuticals, LLC (?Merger Sub?) and APP Pharmaceuticals, Inc. (?APP?), whereby Merger Sub merged into APP with APP continuing as the surviving company and an indirect wholly owned subsidiary of Fresenius SE (the ?Merger?), this option, which was granted on April 9, 2008 and 25% of which vests per year for four years from the anniversary of the grant date, was cancelled in exchange for a cash payment of $357,000, which represents the excess of $23.00 per share over the exercise price per share of this option.